IP Library Granted Patent US 9,215,994
Granted Patent B2
US 9,215,994 · App. 14/625,402 · Granted Dec 22, 2015

Detecting infection in reduced pressure wound treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,215,994
App. No.
14/625,402
Granted
Dec 22, 2015
Kind
B2
Abstract

Provided is a method of detecting infection in a wound caused by an infecting organism at a wound site. Also provided is a system for detecting an infection in a wound at a wound site. Additionally, a porous pad comprising luciferase is provided.

Claims (34)

1. A system for detecting an infection, comprising:

a porous pad adapted to be in contact with a wound site, the porous pad comprising luciferase; and

a photodetector adapted to be positioned adjacent the porous pad and configured to measure light emitted from the porous pad;

whereby the presence of light emitted from the porous pad indicates the presence of an infection in the wound site.

2. The system of claim 1 , wherein the porous pad further comprises luciferin.

3. The system of claim 1 , further comprising a computer linked to the photodetector, wherein the computer is capable of recording the light measurements from the photodetector.

4. The system of claim 3 , wherein the computer is further capable of determining whether the recorded light measurements indicate infection in the wound site.

5. The system of claim 1 , further comprising a drape adapted to provide a substantially airtight cover over the porous pad and the wound site.

6. The system of claim 5 , further comprising:

a reduced-pressure source; and

a conduit fluidly connecting the porous pad to the reduced-pressure source, wherein the conduit is adapted to withdraw a fluid from the wound site in response to the reduced pressure.

7. The system of claim 6 , further comprising a reservoir adapted for collection of the fluid.

8. The system of claim 1 , further comprising a supply line into the porous pad for the introduction of luciferase and luciferin from a source reservoir.

9. The system of claim 6 , wherein the reduced-pressure source is configured to draw adenosine-5′-triphosphate (ATP) from an infection in the wound site into the porous pad.

10. The system of claim 5 , wherein the photodetector is integrated with the drape.

11. The system of claim 8 , wherein the supply line is further adapted for the introduction of an infection-controlling compound to the wound site.

12. The system of claim 11 , wherein the infection-controlling compound comprises an antibiotic.

13. A system for detecting an infection at a wound site, comprising:

a porous pad comprising luciferase and adapted to be in contact with the wound site;

a photodetector adapted to be positioned adjacent the porous pad; and

a supply line fluidly connected to the porous pad and adapted to introduce an infection-controlling compound to the wound site.

14. The system of claim 13 , wherein the porous pad further comprises luciferin.

15. The system of claim 13 , wherein the supply line is further adapted to deliver luciferase and luciferin to the porous pad.

16. The system of claim 13 , further comprising:

a drape adapted to provide a substantially airtight cover over the porous pad and the wound site;

a reduced-pressure source; and

a conduit fluidly connecting the porous pad to the reduced-pressure source.

17. The system of claim 13 , wherein the infection-controlling compound comprises an antibiotic.

18. A method of treating a wound site, comprising:

applying a reduced pressure through a porous pad comprising luciferase to the wound site;

assaying a fluid withdrawn from the wound site for a product of an infection by measuring light emitted from the fluid with a photodetector capable of measuring light and adapted to be positioned adjacent to the porous pad; and

administering an infection-controlling compound through a supply line into the porous pad for introduction to the wound site.

19. The method of claim 18 , wherein the porous pad further comprises luciferin.

20. The method of claim 18 , wherein a source of the infection is a bacterium and the product of the infection is adenosine-5′-triphosphate (ATP).

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066432/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064790/0085 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →